![](/imgs/covers/hs_cover.jpg)
|
African Health Sciences
Makerere University Medical School
ISSN: 1680-6905 EISSN: 1680-6905
Vol. 14, No. 3, 2014, pp. 564-569
|
Bioline Code: hs14086
Full paper language: English
Document type: Study
Document available free of charge
|
|
African Health Sciences, Vol. 14, No. 3, 2014, pp. 564-569
en |
In vitro evidence for bakuchiol’s influence towards drug metabolism through inhibition of UDP-glucuronosyltransferase (UGT) 2B7
Xu, Yu; Li, Peizhong; Zhang, Xin; Wang, Junying; Gu, Dongsheng & Wang, Yao
Abstract
Background: Inhibition of drug-metabolizing enzymes (DMEs) has been regarded as one of the most important reason for clinical drug-drug interaction.
Aim: The aim of the present study is to evaluate the inhibition of bakuchiol towards UDP-glucuronosyltransferase (UGT) 2B isoforms.
Methods: In vitro recombinant UGT2B-catalyzed 4-methylumbelliferone glucuronidation was used as the probe reaction. Dixon plot and Lineweaver-Burk plot were employed to determine the inhibition kinetic type, and nonlinear regression of data was utilized to calculate the inhibition kinetic parameter (Ki). In vitro-in vivo extrapolation (IVIVE) was carried out to predict in vivo inhibition magnitude.
Results: Among the tested UGT2B isoforms, UGT2B7 was inhibited by the strongest intensity. The noncompetitive inhibition was demonstrated by the results obtained from Dixon plot and Lineweaver-Burk plot. The Ki value was calculated to be 10.7 μM. In combination with the reported concentration after an intravenous administration of bakuchiol (15 mg/kg) in rats, the high risk of in vivo inhibition of bakuchiol towards UGT2B7-catalyzed metabolism of drugs was indicated.
Conclusion: All these results provide an important information for the risk evaluation of the clinical utilization of bakuchiol.
Keywords
bakuchiol; drug-drug interaction; drug-metabolizing enzymes
|
|
© Copyright 2014 - African Health Sciences
|
|